Quest Diagnostics (DGX) EVP logs stock sale, option and RSU awards

Rhea-AI Filing Summary

Quest Diagnostics executive Catherine T. Doherty, EVP, Regional Businesses, reported multiple equity transactions. On February 19, 2026, she completed an open-market sale of 1,433 shares of common stock at $204.83 per share under a Rule 10b5-1 sales plan, leaving 68,402 directly held shares.

On February 18, 2026, she received a grant of 13,514 non-qualified stock options at an exercise price of $0.00 per option, vesting in three equal annual installments beginning on the first anniversary of the grant date. She also acquired 2,928 shares of common stock as a restricted stock unit award, with related tax-withholding dispositions of 433 shares at $210.01 and 728 shares at $206.99. In addition, 4,503 shares are held indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doherty Catherine T.

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Regional Businesses

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	02/18/2026		A		2,928	A	$0	70,996	D
Common Stock	02/18/2026		F		433(2)	D	$210.01	70,563	D
Common Stock	02/18/2026		F		728(2)	D	$206.99	69,835	D
Common Stock	02/19/2026		S		1,433(3)	D	$204.83	68,402	D
Common Stock								4,503(4)	I	401(k)/SDCP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$204.96	02/18/2026		A		13,514		(5)	02/18/2036	Common Stock	13,514	$0	13,514	D

Explanation of Responses:

1. Represents an award of restricted stock units.

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units.

3. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

4. These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.

5. The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Catherine T. Doherty	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did DGX executive Catherine Doherty report?

Catherine T. Doherty reported an open-market sale of 1,433 Quest Diagnostics shares and several equity awards, including stock options and restricted stock units, plus related tax-withholding share dispositions and holdings in company retirement and deferred compensation plans.

How many Quest Diagnostics shares did Catherine Doherty sell on this Form 4?

Catherine Doherty sold 1,433 shares of Quest Diagnostics common stock at a price of $204.83 per share. The filing notes this exercise and sale were effected pursuant to a Rule 10b5-1 sales plan she had previously adopted.

What new stock option award did Catherine Doherty receive from DGX?

She received a grant of 13,514 non-qualified stock options with an exercise price of $0.00 per option. These options vest in three equal annual installments, beginning on the first annual anniversary of the grant date, according to the Form 4 disclosure.

Did Catherine Doherty receive restricted stock units from Quest Diagnostics?

Yes. The Form 4 states that 2,928 shares of common stock represent an award of restricted stock units. Some additional shares, 433 and 728 respectively, were disposed of to Quest Diagnostics solely to cover tax withholding obligations from vesting.

How many Quest Diagnostics shares does Catherine Doherty hold after these transactions?

After these transactions, Catherine Doherty directly holds 68,402 shares of Quest Diagnostics common stock. She also has 13,514 stock options from the new grant and 4,503 shares held indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan.

Were any DGX shares disposed of for tax withholding purposes?

Yes. The filing reports dispositions of 433 shares at $210.01 and 728 shares at $206.99. Footnotes explain these were transfers of common stock back to Quest Diagnostics solely to satisfy tax withholding obligations arising from the vesting of restricted stock units.